Form 4: Viking Therapeutics CFO Reports Stock Transactions Following Performance-Based Vesting

Viking Therapeutics' CFO, Greg Zante, reports acquisition and disposal of company stock related to performance-based restricted stock units.

Summary

• On March 1, 2024, Viking Therapeutics' CFO, Greg Zante, acquired 31,667 shares of common stock due to the vesting of performance restricted stock units.
• The vesting occurred because a non-financial performance goal was achieved, relating to a grant made on January 3, 2023.
• 33.33% of the performance restricted stock units vested on March 1, 2024.
• Also on March 1, 2024, 20,093 shares were withheld by the issuer to satisfy tax obligations related to the vesting.
• The price per share for the tax withholding was $85.22.
• Following these transactions, Zante directly owns 192,304 shares of Viking Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects routine stock transactions by an executive. The vesting suggests a performance goal was met, which is mildly positive.

Positives

• The vesting of performance restricted stock units indicates the achievement of a non-financial performance goal, which could be viewed positively.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade in their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• The vesting of stock options and subsequent tax withholding may have a minor positive impact on shareholder confidence due to the achievement of performance goals.

Key Dates